Company intelligence / Profile preview

SATeva Pharmaceuticals Europe

Ownership: Private
Development stage: Other

Overview

SATeva Pharmaceuticals is a biotechnology company focused on the development of novel therapeutic compounds targeting the endocannabinoid system. The company specializes in the design and synthesis of selective cannabinoid receptor ligands to treat a variety of conditions, including chronic pain, inflammation, and neurological disorders. By leveraging its expertise in medicinal chemistry, SATeva aims to create highly specific small molecules that minimize off-target effects while maximizing therapeutic efficacy. The European division serves as a hub for research and development activities within the region.

Therapeutic areas: ImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on SATeva Pharmaceuticals Europe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SATeva Pharmaceuticals Europe.

Explore the full profile